Access would depend on a person's ability to pay
On the last day of March 2022, Brazil's health regulator Anvisa extended a carefully bounded hand toward a new chapter in pandemic medicine, granting emergency authorization for Paxlovid — an oral antiviral combination — to treat adults at risk of severe COVID-19 progression. The decision, unanimous among board members, reflects both the ingenuity of modern pharmacology and the persistent inequities of public health: a drug approved, but sold commercially, in a country where vaccines remain free. It is a moment that captures the enduring tension between scientific possibility and the human systems through which that possibility must travel.
- Brazil still faced critical gaps in COVID-19 treatment options in early 2022, with drug shortages rooted in high costs, poor distribution, and inappropriate prescribing — making Paxlovid's arrival feel urgent.
- The approval is tightly constrained: only for adults already infected, not requiring oxygen but at genuine risk of deterioration, and explicitly forbidden for minors, pregnant women, or preventive use.
- Regulators moved to contain risk through mandatory drug interaction warnings, guidance letters to healthcare providers, required adverse event reporting, and quarterly updates on the drug's international regulatory standing.
- Directors were careful to draw a line between the antiviral and the vaccine — one is a commercial product, the other a free public good — raising immediate questions about who will actually be able to afford treatment.
- The unanimous board vote signals institutional confidence, but the real test lies ahead: whether affordability and healthcare system capacity will allow the approval to translate into lives protected.
Brazil's health regulator Anvisa granted emergency authorization for Paxlovid on March 30th, clearing the antiviral combination of nirmatrelvir and ritonavir for use in a carefully defined population. The drug is intended for adults who have tested positive for COVID-19, are not yet requiring supplemental oxygen, but face real risk of severe illness. Taken orally, its purpose is to prevent deterioration — not to prevent infection. Regulators were explicit: it is not for minors, not for pregnant women, and not for preventive use.
Anvisa director Meiruze Souza Freitas framed the approval as a response to persistent gaps in treatment access, citing prohibitive costs, weak distribution systems, and inappropriate prescribing as ongoing problems. Fellow director Rômison Mota noted that similar authorizations had already been granted in the United States, Canada, and Mexico. Director Alex Campos raised a point that cut to the heart of the matter: unlike vaccines, which are distributed free of charge, Paxlovid would be sold commercially — meaning access would hinge on a patient's ability to pay.
The technical review was thorough. Anvisa's pharmacovigilance team identified significant drug interactions, mandating explicit contraindication warnings for concurrent use with apalutamida, a prostate cancer medication. Healthcare providers were to receive guidance letters on managing interactions and necessary precautions. The manufacturer was required to submit ongoing usage data from Brazil, report adverse events, provide clinical study updates, and file quarterly reports on the drug's regulatory status abroad.
Director Cristiane Jourdan confirmed that the evidence showed benefits outweighing risks, and the board voted unanimously in favor. Each member emphasized different dimensions of the decision, but all arrived at the same conclusion: the drug should be available, under strict conditions and close monitoring. Whether those conditions will translate into meaningful access for Brazilian patients — or whether cost will quietly become the true barrier — remains the open question.
Brazil's health regulator cleared the way for Paxlovid on Wednesday, March 30th, granting emergency authorization for the antiviral combination drug to treat COVID-19 in a narrowly defined population. The medication, manufactured by Wyeth and composed of nirmatrelvir and ritonavir working in tandem, represents a new tool in the country's pandemic response—but with significant constraints built into its approval.
The drug is intended for adults who have tested positive for the virus, who are not yet requiring supplemental oxygen, but who face genuine risk of deteriorating into severe illness. It is taken orally and works primarily to prevent that downward spiral—to keep people from getting worse. But the approval comes with clear boundaries: it cannot be given to anyone under eighteen, and it is contraindicated entirely for pregnant women or those planning pregnancy during treatment. This is not a preventive medication, and regulators were emphatic on that point. It is a treatment for people already infected.
Meiruze Souza Freitas, a director at Anvisa, framed the decision as a response to urgent public health need. She acknowledged that the pandemic had created unprecedented challenges and that gaps in treatment availability remained a critical problem. The shortage of essential medications, she noted, stemmed from multiple sources: prohibitive costs, inefficient procurement and distribution systems, uncertain product quality, and inappropriate prescribing practices. Approving Paxlovid, in her view, helped narrow that gap. Other directors reinforced the boundaries of the authorization. Rômison Mota stressed that this was not a preventive agent and that similar approvals had already been granted in the United States, Canada, and Mexico. Alex Campos made a different but equally important point: Paxlovid is not a substitute for vaccination, which remains available free of charge. The antiviral, by contrast, would be sold commercially—meaning access would depend on a person's ability to pay.
The technical review process revealed the complexity underlying even an emergency authorization. Anvisa's pharmacovigilance team, led by Helaine Capucho, identified drug interactions requiring careful management. The agency mandated that the medication's label include explicit contraindications for concurrent use with apalutamida, a prostate cancer drug. The team also required that healthcare providers receive guidance letters explaining how Paxlovid interacts with other medications and what precautions are necessary. Gustavo Mendes, the agency's general manager for medications and biological products, outlined additional safeguards: the manufacturer must provide ongoing data about how the drug is being used in Brazil, report any adverse events, submit clinical and non-clinical study reports, and file quarterly updates on the drug's regulatory status in other countries.
Cristiane Jourdan, another Anvisa director, confirmed that the evidence showed benefits outweighing risks and that the risk management measures aligned with international standards. The approval was unanimous among the board members present, each emphasizing different aspects of the decision but converging on the same conclusion: the drug should be available, but only under strict conditions and with robust monitoring. What remains to be seen is whether those conditions will translate into meaningful access for Brazilian patients, or whether cost will become the real barrier to treatment.
Citas Notables
The pandemic created unprecedented challenges and gaps in treatment availability remained a critical problem, stemming from prohibitive costs, inefficient distribution, uncertain product quality, and inappropriate prescribing.— Meiruze Souza Freitas, Anvisa director
Paxlovid is not a substitute for vaccination, which remains available free of charge. The antiviral would be sold commercially.— Alex Campos, Anvisa director
La Conversación del Hearth Otra perspectiva de la historia
Why did Anvisa need to approve this in an emergency framework rather than through standard review?
Because the pandemic was still active and people were dying. Standard review takes months or years. Emergency authorization compresses that timeline when there's clear evidence of benefit and the alternative is doing nothing.
But if it's emergency approval, doesn't that mean they're taking more risk?
Not necessarily more risk—different risk. They're accepting some unknowns about long-term effects in exchange for preventing immediate harm. The key is they built in monitoring. They're not just handing it out and hoping for the best.
The article mentions it won't be free. How does that change things?
It changes everything for access. A vaccine that's free reaches millions. A drug you have to buy reaches whoever can afford it. In Brazil, that's a real constraint. The drug works, but only for people who can pay.
What about those drug interactions they mentioned—the apalutamida thing?
That's the regulator being careful. Some drugs interfere with each other in ways that make one or both ineffective or dangerous. Paxlovid has several of those interactions. So they're requiring doctors to know about them before prescribing.
Is this approval a sign the pandemic was ending in Brazil?
Not necessarily. It's a sign they finally had a treatment option worth distributing. The pandemic was still very much happening. This was about giving doctors another tool when vaccines alone weren't stopping severe disease.